Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Janux Therapeutics | 2024 | Post Ipo Equity | $350.0M | La Jolla |
| Bia Energy | 2024 | Convertible Note | $8.5M | Bogotá |
| ADCendo | 2024 | Series B | $135.0M | Copenhagen |
| Cortica | 2024 | Series Unknown | $80.0M | San Diego |
| Synapticure | 2024 | Series A | $25.0M | Chicago |
| Metsera | 2024 | Series B | $215.0M | New York |
| Trace Neuroscience | 2024 | Series A | $101.0M | South San Francisco |
| Alentis Therapeutics | 2024 | Series D | $181.4M | Allschwil |
| Avalo Therapeutics | 2024 | Post Ipo Equity | $69.4M | Rockville |
| Alpha-9 Oncology | 2024 | Series C | $175.0M | Vancouver |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 301 | Janux Therapeutics | Post Ipo Equity | $350.0M | La Jolla, United States |
| 302 | Bia Energy | Convertible Note | $8.5M | Bogotá, Colombia |
| 303 | ADCendo | Series B | $135.0M | Copenhagen, Denmark |
| 304 | Cortica | Series Unknown | $80.0M | San Diego, United States |
| 305 | Synapticure | Series A | $25.0M | Chicago, United States |
| 306 | Metsera | Series B | $215.0M | New York, United States |
| 307 | Trace Neuroscience | Series A | $101.0M | South San Francisco, United States |
| 308 | Alentis Therapeutics | Series D | $181.4M | Allschwil, Switzerland |
| 309 | Avalo Therapeutics | Post Ipo Equity | $69.4M | Rockville, United States |
| 310 | Alpha-9 Oncology | Series C | $175.0M | Vancouver, Canada |
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
Bia Energy is transforming LatAm’s power sector with smart meters and a digital platform for real-time control, savings, and sustainability.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs.
Cortica provides neurological therapies for children with autism and other developmental differences.
We provide neurodegenerative disease patients with expert MDs and 24/7 wrap around care, no matter where you live in the US
Metsera is a clinical‐stage biotech firm developing oral & injectable hormone therapies to treat obesity & related metabolic diseases.
Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients.
ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Alpha-9 Oncology is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
Ervaxx is illuminating the immune interface to develop new cancer therapies.
Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals.
Convergent Therapeutics is a pharmaceutical company that focuses on developing radiopharmaceutical therapies for prostate cancer.
Navigator Medicines operate as a biotech company.
Elektrofi develops hyper concentration microparticle technology for subcutaneous biologic medicine delivery.
Halda Therapeutics is a research-stage drug discovery company.
Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat cancer.
MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.
Outpace Bio develops innovative cell therapies to enhance cancer treatment efficacy.
Day One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.
Vesta Healthcare is a technology and clinical services organization that offers virtual care services.
Magenta Medical is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure.
LENZ Therapeutics operates as an organization engaged in the late-stage clinical development of pharmaceuticals for the eyes.
AM Batteries manufactures Li-ion batteries using solvent-free electrode manufacturing technology.
Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.
RA Capital Management has invested in 413 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Medical. The firm invests across 25 different industry categories.
Among tracked funding rounds, Janux Therapeutics received $350.0M in a Post Ipo Equity round. RA Capital Management's total known invested capital is $19.0B.
RA Capital Management's average investment size is $91.5M across its portfolio of 413 companies.
Recent RA Capital Management portfolio additions include Janux Therapeutics, Bia Energy, ADCendo, Cortica, Synapticure. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors